Gilead Sciences (NASDAQ:GILD) week 3 Harvoni TRx was 1984, up 79% week-over-week, according to RBC analyst Michael J. Yee, citing IMS. NRx was 1973, up 80%. Harvoni plus Sovaldi TRx was 6286 and NRx was 3326, up 20% and 42%, respectively.
"So far, Harvoni launch is outpacing Sovaldi launch despite being only approved for GT1 (~70% of HCV) vs. Sovaldi for GT 1,2,3,4. For 2015, taking into account this smaller indication as well as the competition expected in 2015, volume on Harvoni would have to approx match the volume on Sovaldi (100k as of Q3) in 2014 to meet or beat Street 2015 US estimates ~$12B," said Yee.
Disclosure: The author is long GILD.